Axon Enterprise, Inc (NASDAQ:AXON) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Axon Enterprise, Inc (NASDAQ:AXON) have been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $805.7143.

A number of equities analysts recently issued reports on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. The Goldman Sachs Group cut their price objective on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a report on Tuesday. Barclays dropped their target price on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Finally, Royal Bank Of Canada began coverage on shares of Axon Enterprise in a research report on Monday, November 17th. They set an “outperform” rating and a $860.00 price target for the company.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $451.29 on Wednesday. The company has a 50 day moving average price of $575.49 and a 200 day moving average price of $664.42. The firm has a market capitalization of $35.61 billion, a P/E ratio of 142.81, a PEG ratio of 13.86 and a beta of 1.48. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57. Axon Enterprise has a 52 week low of $434.62 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The company had revenue of $710.64 million during the quarter, compared to analysts’ expectations of $704.83 million. During the same period in the prior year, the business posted $1.45 EPS. The company’s quarterly revenue was up 30.6% on a year-over-year basis. Sell-side analysts expect that Axon Enterprise will post 5.8 EPS for the current year.

Insider Activity

In other news, insider Jeffrey C. Kunins sold 1,797 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $539.23, for a total value of $968,996.31. Following the completion of the transaction, the insider owned 83,485 shares of the company’s stock, valued at $45,017,616.55. The trade was a 2.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $551.92, for a total value of $5,519,200.00. Following the sale, the chief executive officer directly owned 3,110,997 shares in the company, valued at approximately $1,717,021,464.24. This trade represents a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 60,540 shares of company stock valued at $34,684,738 over the last quarter. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Westside Investment Management Inc. grew its stake in Axon Enterprise by 4.8% in the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 13 shares in the last quarter. CVA Family Office LLC lifted its holdings in Axon Enterprise by 26.9% during the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock worth $55,000 after buying an additional 14 shares during the last quarter. Newbridge Financial Services Group Inc. grew its position in shares of Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after acquiring an additional 14 shares in the last quarter. Vicus Capital grew its position in shares of Axon Enterprise by 3.7% in the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 14 shares in the last quarter. Finally, Evergreen Capital Management LLC increased its holdings in shares of Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after acquiring an additional 15 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.